<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317707</url>
  </required_header>
  <id_info>
    <org_study_id>R&amp;P</org_study_id>
    <nct_id>NCT00317707</nct_id>
  </id_info>
  <brief_title>Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk</brief_title>
  <official_title>Risk and Prevention Study: Optimisation of the Preventive Strategies and Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the everyday practice cardiovascular prevention in people at high risk is still
      unsatisfactory and treatments with documented efficacy are generally under-used.

      Polyunsaturated fatty acids of marine origin (n-3 PUFA) are the latest more promising
      strategy to improve prognosis in these patients.

      The Risk and Prevention study combines an epidemiological and an experimental approach in
      order to:

        1. Verify the possibility to optimise cardiovascular prevention in subjects at high risk by
           planning the intervention with patients and setting individual goals (outcome study)

        2. Evaluate the efficacy of a long term n-3 PUFA treatment in reducing the incidence of
           cardiovascular events, through a controlled, randomised, double blind clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular deaths and hospitalization for cardiovascular causes</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12513</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>N-3 PUFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Olive oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-3 Polyunsaturated Fatty Acids</intervention_name>
    <description>Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA</description>
    <arm_group_label>N-3 PUFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo: Olive oil</intervention_name>
    <description>Each subject assigned to the control group will receive 1 g/day capsule of olive oil.</description>
    <arm_group_label>Olive oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Multiple risk factors:

               -  diabetes,

               -  age =&gt; 65 years,

               -  male sex,

               -  hypertension,

               -  hypercholesterolemia,

               -  smoking,

               -  obesity,

               -  family history of premature cardiovascular disease;

          -  Previous manifestations of atherosclerotic disease (ischemic stoke, transient ischemic
             attack [TIA], peripheral artery disease, previous arterial revascularisation
             procedures, angina pectoris)

        Exclusion Criteria:

          -  Contraindications (known allergies to n-3 PUFA) or indications (previous myocardial
             infarction) for the treatment with n-3 PUFA

          -  Serious comorbidity with an unfavourable prognosis over the short term

          -  Expected non compliance over a long period of time

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tombesi Massimo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centro Studi e Ricerca in Medicina Generale, Monza, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tognoni Gianni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mario Negri Institute for Pharmacological Research, Milan, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mario Negri Institute for Pharmacological Research</name>
      <address>
        <city>Milan</city>
        <zip>20156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2006</study_first_submitted>
  <study_first_submitted_qc>April 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2006</study_first_posted>
  <last_update_submitted>January 17, 2012</last_update_submitted>
  <last_update_submitted_qc>January 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular risk</keyword>
  <keyword>cardiovascular diseases</keyword>
  <keyword>cardiovascular prevention</keyword>
  <keyword>polyunsaturated fatty acids</keyword>
  <keyword>diabetes</keyword>
  <keyword>hypertension</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

